CNS Pain Expansion Target neurology and pain clinics with the Phase 2 program for diabetic peripheral neuropathic pain and pursue rapid indication expansion into PTSD, insomnia, and chronic lower back pain using Syqe's precision inhalation platform to deliver sub-hallucinogenic dosing and durable symptom relief.

Veteran Market Access Leverage proven real-world use and Israeli MOD reimbursement to unlock defense and veterans health opportunities in new markets, pursuing DoD/VA collaborations and trauma-focused care contracts backed by compelling patient outcomes and reduced impairment.

Platform Licensing Offer the SyqeAir delivery platform to other CNS-acting drugs, creating a recurring revenue stream through licensing or co-development with pharma partners in neurology, psychiatry, and pain management.

Regulatory Advantage Highlight a clear regulatory pathway to FDA approval and a scalable plan for rapid indication expansion to attract co-development and early-access deals, leveraging Phase 2 data and real-world evidence to de-risk partner diligence.

Economic Value Frame the value proposition around precise dosing, safety, and reduced medication burden to drive adoption with hospitals, payers, and health systems, emphasizing potential cost savings, improved function, and reimbursement viability.